Whittier Trust Co. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 3.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,143 shares of the company’s stock after purchasing an additional 333 shares during the period. Whittier Trust Co.’s holdings in Zoetis were worth $1,932,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of the stock. Norges Bank bought a new stake in Zoetis during the 4th quarter worth about $980,646,000. Price T Rowe Associates Inc. MD lifted its holdings in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after buying an additional 3,244,074 shares during the period. Sarasin & Partners LLP grew its holdings in Zoetis by 546.3% during the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after acquiring an additional 1,904,899 shares during the period. Swedbank AB acquired a new position in shares of Zoetis in the 1st quarter valued at $210,815,000. Finally, Public Employees Retirement Association of Colorado bought a new position in shares of Zoetis in the 4th quarter worth $242,757,000. 92.80% of the stock is owned by institutional investors.
Zoetis Trading Down 0.0 %
ZTS opened at $182.86 on Friday. The stock has a market capitalization of $82.84 billion, a P/E ratio of 35.23, a P/E/G ratio of 2.78 and a beta of 0.86. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The firm’s fifty day simple moving average is $179.29 and its 200 day simple moving average is $174.63.
Analysts Set New Price Targets
Several research firms have weighed in on ZTS. The Goldman Sachs Group cut their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. HSBC cut their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler increased their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $217.11.
View Our Latest Stock Report on Zoetis
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- 5 discounted opportunities for dividend growth investors
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
- How is Compound Interest Calculated?
- 3M’s Turnaround Story Will Continue This Year
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Dollar General’s Stock: A Warning Sign for the Average American?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.